We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

357 hedge funds and large institutions have $4.15B invested in Ligand Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 133 increasing their positions, 115 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 43

22% more call options, than puts

Call options by funds: $8.48M | Put options by funds: $6.95M

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

7% more capital invested

Capital invested by funds: $3.89B → $4.15B (+$264M)

2% more funds holding

Funds holding: 349 → 357 (+8)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0.18% less ownership

Funds ownership: 104.47% → 104.29% (-0.18%)

Holders
357
Holders Change
+8
Holders Change %
+2.29%
% of All Funds
4.39%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
59
Increased
133
Reduced
115
Closed
43
Calls
$8.48M
Puts
$6.95M
Net Calls
+$1.54M
Net Calls Change
-$3.42M

Top Buyers

1
Invesco
Invesco
Georgia
+$60.8M
2
NCGI
Next Century Growth Investors
Minnesota
+$19M
3
Bessemer Group
Bessemer Group
New Jersey
+$16.7M
4
Franklin Resources
Franklin Resources
California
+$15.2M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.9M

Top Sellers

1
UBS AM
UBS AM
Illinois
-$29.8M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$21M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$18.9M
4
NAMI
Nomura Asset Management International
Pennsylvania
-$14M
5
Goldman Sachs
Goldman Sachs
New York
-$9.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
PWMG
351
Prestige Wealth Management Group
New Jersey
$400 +$396 +2 New
VWM
352
Vermillion Wealth Management
Minnesota
$399 +$396 +2 New
AWM
353
Abound Wealth Management
Tennessee
$200 – – –
RWM
354
Rialto Wealth Management
New York
$200 – – –
SS
355
SBI Securities
Japan
$200 – – –
GIA
356
GHP Investment Advisors
Colorado
$200 +$198 +1 New
SIC
357
SJS Investment Consulting
Ohio
$200 +$198 +1 New
CIBC World Market
358
CIBC World Market
Ontario, Canada
– -$4.85M -25,630 Closed
EI
359
EAM Investors
California
– -$3.99M -21,092 Closed
TI
360
Trexquant Investment
Connecticut
– -$2.18M -11,550 Closed
DekaBank Deutsche Girozentrale
361
DekaBank Deutsche Girozentrale
Germany
– -$859K -11,185 Closed
OAM
362
OP Asset Management
– -$1.36M -7,212 Closed
EA
363
Ellsworth Advisors
Ohio
– -$1.29M -6,565 Closed
GC
364
Guggenheim Capital
Illinois
– -$994K -5,257 Closed
QT
365
Quantbot Technologies
New York
– -$878K -4,644 Closed
BA
366
Bridgewater Associates
Connecticut
– -$795K -4,207 Closed
IQI
367
Integrated Quantitative Investments
Washington
– -$687K -3,635 Closed
DP
368
Diadema Partners
New Jersey
– -$565K -2,987 Closed
Simplex Trading
369
Simplex Trading
Illinois
– -$407K -2,055 Closed
FC
370
FORA Capital
Florida
– -$337K -1,922 Closed
Canada Pension Plan Investment Board
371
Canada Pension Plan Investment Board
Ontario, Canada
– -$303K -1,600 Closed
Cerity Partners
372
Cerity Partners
New York
– -$289K -1,531 Closed
AGM
373
Alpine Global Management
New York
– -$284K -1,500 Closed
Envestnet Portfolio Solutions
374
Envestnet Portfolio Solutions
Illinois
– -$266K -1,407 Closed
PAS
375
Park Avenue Securities
New York
– -$265K -1,402 Closed
12 13 14
15
16

LGND Hedge Fund Activity: Q1 2026 in Review

357 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2026, worth a combined $4.15B — up 6.8% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new LGND positions and 43 closed out — a net gain of 16 holders — while 133 added to existing stakes and 115 trimmed.

The largest buyer was Invesco, adding an estimated $60.8M. The largest seller was UBS AM, cutting an estimated $29.8M.

  • 357 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2026, up from 349 in Q4 2025.
  • Funds reported $4.15B of Ligand Pharmaceuticals stock for Q1 2026, up 6.8% quarter-over-quarter.
  • 59 funds opened new Ligand Pharmaceuticals positions in Q1 2026 and 43 closed out, a net change of +16 holders.
  • The largest Ligand Pharmaceuticals buyer in Q1 2026 was Invesco, an estimated $60.8M added.
  • The largest Ligand Pharmaceuticals seller in Q1 2026 was UBS AM, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2026.